MN-KINDEVA-DRUG-DELIVERY
At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award. This prestigious award is given once every two years at RDD Conferences to one scientist who has been voted by his or her peers to have pioneered significant developments in one or more aspects of the science and technology surrounding respiratory drug delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508931671/en/
Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug Delivery (RDD) Conference. Also pictured (from left to right): Michael Hindle, Ph.D., Professor, School of Pharmacy at Virginia Commonwealth University, Stephen Stein, Scientific Director of Inhalation Product Development at Kindeva, and Milton Boyer, CEO at Kindeva. (Photo: Business Wire)
Patton has been one of the most influential scientists in the field of respiratory drug delivery and is a champion in the field of pulmonary delivery of large molecules and biologics. He has published more than 100 publications, has more than 40 patents, and has founded or co-founded six drug delivery companies, including iPharma Labs, a company that Kindeva acquired in 2022.
“John’s research and development expertise, coupled with the myriad publications he authored, have helped pave the way for respiratory delivery to be utilized by researchers and companies for the treatment of other diseases,” said Kindeva’s Global Chief Commercial Officer, David Stevens. “John’s passion and conviction with respect to the applications of drug delivery to and through the lungs, and in particular his pioneering work progressing pulmonary delivery of biologics, has been nothing short of inspiring. John has made and continues to make a tremendous contribution to both Kindeva and the wider industry. On behalf of all his colleagues at Kindeva, we congratulate John. It is a privilege to work alongside him and benefit from his technical vision and boundless enthusiasm for inhaled medicine.”
Kindeva’s application in inhaled biologics spans complex therapeutic treatments from local to deep lung (systemic) delivery — including lung fibrosis, asthma/COPD, cardiovascular, and infectious diseases — and encompasses a wealth of expertise in developing solutions that address insulin needs, cold chain requirements, and more.
Read more about this award as well as Kindeva’s advancements in biologic drug development.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508931671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCTO Revolutionizes Vehicle Safety with AI: Introducing the Proactive and Predictive Anti-Theft System10.12.2025 10:00:00 CET | Press release
Anticipating a theft before it happens. This is the goal of OCTO’s new predictive anti-theft system, developed by the global leader in telematics and data analytics solutions for connected mobility. The new technology combines artificial intelligence, machine learning, and advanced sensors to deliver real-time, personalized vehicle protection capable of recognizing risk signals before a theft event occurs. Drawing on more than 22 years of experience and 610 billion kilometers of driving data, the system transforms the paradigm of vehicle security from reactive to proactive. This approach enables prevention rather than mere response, increasing protection for both private vehicles and corporate fleets. The main features include: Tampering detection: sensors identify attempts to access or remove the devices. Abnormal vehicle movement: the system detects vehicle dragging or lifting while the engine is off. Loss of connection between the devices installed on the vehicle: when one of the tw
Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Awards 202510.12.2025 09:55:00 CET | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, has won the CX Catalyst award for Impact at The Fast Mode Awards 2025. The awards, hosted by leading independent media, research, and analysis platform The Fast Mode, recognises industry visionaries and transformative innovations redefining the global telecoms space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210927009/en/ Tecnotree Emerges as CX Catalyst Winner for Impact at The Fast Mode Awards 2025 Tecnotree’s award‑winning CX platform delivers omnichannel engagement for operators across voice, SMS, social media, chat, web, and in-app channels. The solution uses AI- and ML-driven analytics to identify customer behaviour, preferences and lifecycle stages — enabling proactive engagement and churn prevention. Real-time personalization and decisioning ensure context-aware interactions, while campaign orchestration unifie
Tyk Marks 10 Years in Business by Proving British Tech Can Grow Responsibly10.12.2025 09:30:00 CET | Press release
Tyk, the independent UK software company powering millions of digital transactions worldwide, is marking its tenth anniversary with B Corp certification - a milestone that recognises a decade of growth built on purpose, not hype. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209886821/en/ Tyk Founders, Martin Buhr (Left), James Hirst (Right) Founded in London in 2014 by Martin Buhr, Tyk began as a one-man side project and has grown into a company of 150 people in 30 countries. Its API management platform now underpins the digital infrastructure of banks, retailers and telcos across more than 100 markets including NatWest, SoundCloud, Zeiss, T-Mobile and Dollar General, powering over 100 million people’s financial transactions daily. From its inception, Tyk has challenged the conventions of the tech industry. It built a profitable business without offices or a “growth at all costs” mentality, long before remote-first work
Sainte Catherine, Institut du Cancer Avignon-Provence (ICAP), Becomes the First Center in Europe to Implement the Varian Latest Halcyon Advancements with Identify integration, PerfectKinetix Dynamic Couch and HyperSight for Personalized Radiotherapy10.12.2025 09:00:00 CET | Press release
Institut du Cancer Avignon-Provence (ICAP), and Varian, a Siemens Healthineers company, announced today the first European installation of the Halcyon version 5.0 radiotherapy platform, combined with IDENTIFY real-time motion management, and the PerfectKinetix Dynamic Couch. This milestone marks a significant step forward in delivering more precise, efficient, and personalized radiotherapy, while enhancing the overall patient experience. The latest evolution of Varian’s Halcyon platform brings together enhanced patient positioning, real-time motion management with IDENTIFY, and embedded high-quality HyperSight imaging. ICAP’s adoption of this ecosystem reflects its commitment to offering patients in the region access to the latest innovations in radiation oncology. Advancing Personalized Care The combination of Halcyon 5.0 and IDENTIFY 5.0 enables clinicians to deliver treatment more effectively by supporting individualized care plans. IDENTIFY* integration is designed to improve posit
L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 08:30:00 CET | Press release
The GDC, established in LTTS’ Mobility segment, will strengthen PALFINGER’s localization roadmap and next-gen digital transformation initiatives L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom